Business Wire

CA-VEEVA-SYSTEMS-INC.

Share
Veeva Becomes First Public Company to Convert to a Public Benefit Corporation

Veeva Systems (NYSE: VEEV) announced that in an overwhelming majority vote, 99% of voting shareholders support the company’s proposal to become a public benefit corporation (PBC), including the vast majority of Veeva’s largest shareholders. With shareholder approval, Veeva will become a public benefit corporation on Feb. 1, 2021, making it the first publicly traded company and largest-ever to convert to a PBC.

As a PBC, Veeva will remain a for-profit corporation but will be legally responsible to balance the interests of multiple stakeholders, including customers, employees, partners, and shareholders. It will also broaden its certificate of incorporation to include a public benefit purpose, ‘to help make the industries it serves more productive and create high-quality employment opportunities.’

A key technology partner to the life sciences industry, Veeva is dedicated to customers’ mission to advance human health and wellbeing. This move aligns Veeva’s legal charter with this broader mission and the company’s core values, including do the right thing, customer success, and employee success.

“We’ve always operated in the best interests of our customers, employees, communities, and shareholders,” said Peter Gassner, founder and CEO of Veeva Systems. “We’re excited to take the important step to put this in our legal charter so we can ensure Veeva’s accountability to all stakeholders continues for decades to come.”

Veeva’s proposal to declassify its board of directors also received near unanimous approval by shareholders.

What Veeva Stakeholders are Saying:

“Veeva has been a partner for many years and is deeply committed to Dicerna's success and our mission to develop innovative treatments for patients in need,” said Rob Ciappenelli, chief commercial officer at Dicerna Pharmaceuticals, Inc. “We look forward to delivering innovative solutions to patient communities with Veeva’s continued support.”

“I’m proud to be part of a company that has a broader purpose and isn’t only about the money,” said Sayaka So, engineering manager at Veeva Systems. “As part of a public benefit corporation, I know my contributions will help make a positive impact in the world.”

“Veeva’s PBC conversion combined with their annual purpose reporting is leading the way for U.S. public companies to put corporate purpose into action,” said Timothy Youmans, lead-North America, EOS at Federated Hermes. “This is a great example of a public company board aligning stakeholder-inclusive purpose and corporate governance in the interest of long-term value and societal benefit.”

Additional Information

Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu

About Veeva Systems

Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 950 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu .

Forward-looking Statements

This release contains forward-looking statements, including the statements regarding the expected impact and benefits of Veeva’s conversion to a Delaware public benefit corporation. Any forward-looking statements contained in this press release are based upon Veeva’s current expectations, historical performance and its current plans and estimates, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including potentially negative reactions to our conversion to a Delaware public benefit corporation. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended October 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov . Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

® 2021 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.

Veeva Systems Inc. owns other registered and unregistered trademarks.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis26.10.2025 01:55:00 CEST | Press release

Eight-week results from the TRuE-AD4 trial demonstrate treatment with Opzelura® (ruxolitinib cream) significantly improved the clinical signs of atopic dermatitis (AD), including improved itch as early as Day 2, and was well tolerated in adults with moderate AD who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) At Week 8, 70% of patients treated with Opzelura achieved a ≥75% improvement in the Eczema Area and Severity Index (EASI75) and 61.3% achieved Investigator’s Global Assessment Treatment Success (IGA-TS), co-primary endpoints of the study Based on these results, Incyte expects to file a Type-II variation application for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU) by end of year Incyte (Nasdaq:INCY) today announced new data from the Phase 3b TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib cream) in adults with moder

MultiBank Group and Khabib Nurmagomedov Launch an Exclusive Worldwide Multi-Billion-Dollar Joint Venture to Build the World’s First Regulated Tokenized Sports Ecosystem25.10.2025 10:24:00 CEST | Press release

MultiBank Group, the world’s largest financial derivatives institution, has entered into an exclusive worldwide multi-billion-dollar joint venture with global sports icon and undefeated UFC champion Khabib Nurmagomedov (29-0) to create a first-of-its-kind regulated ecosystem connecting global finance, sports and technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251025540563/en/ MultiBank Group and Khabib Nurmagomedov Launch an Exclusive Worldwide Multi-Billion-Dollar Joint Venture to Build the World’s First Regulated Tokenized Sports Ecosystem The partnership will culminate in the creation of a multi-billion-dollar joint venture, MultiBank Khabib LLC, uniting two global powerhouses: MultiBank Group, a leader in regulated financial excellence, and Khabib Nurmagomedov, undefeated in the octagon and whose influence extends far beyond sport.The company will operate from MultiBank Group’s headquarters in Dubai, building

Altimetrik Completes Acquisition of SLK Software, Uniting Strengths to Unlock Value through AI-First and Digital Enablement24.10.2025 18:57:00 CEST | Press release

Altimetrik today announced the successful completion of its acquisition of SLK Software, marking a major milestone in the company’s journey to build a digital engineering powerhouse. As part of this transition, SLK Software will now operate under its new identity as “SLK, an Altimetrik company”. The integration brings together Altimetrik’s AI-first, data-led innovation capabilities with SLK’s strength in Intelligent Enterprise, Digital Operations, Intelligent Infrastructure and Automation and Quality Engineering - spanning the entire digital enablement value chain from strategy and design to engineering and managed services. Anchored in a Practitioner-Led approach, the unified organization merges deep domain expertise with modern platforms and digital operating models to deliver bite-size, outcome-focused execution that accelerates time-to-value. “I am thrilled to officially welcome the SLK team to Altimetrik, bringing together two organizations driven by purpose, innovation, and an un

Andersen Consulting samarbejder med Acronotics om at udbygge AI-styrede digitale transformationskapaciteter24.10.2025 17:55:00 CEST | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med Acronotics, et hurtigt voksende digitalt konsulentfirma med hovedsæde i Storbritannien og afdelinger i USA og Indien. Som specialist i AI-drevet forretningstransformation samarbejder Acronotics med Fortune 500-virksomheder om at fremskynde den digitale transformation ved hjælp af kunstig intelligens. Virksomheden har dyb ekspertise inden for produktion, bankvirksomhed og finansielle tjenester, detailhandel, hurtigt omsættelige forbrugsgoder og højteknologiske industrier med stærkt fokus på AI/ML, generativ AI og RPA-teknologi. Acronotics leverer end-to-end-tjenester, herunder design, udvikling og implementering af Agentic AI og RPA-baserede procesautomatiseringsløsninger. Ved hjælp af sin egenudviklede automatiserede digitale medarbejderstyringsplatform, Radium.ai, hjælper virksomheden sine kunder med at administrere og overvåge deres digitale arbejdsstyrke effek

LambdaTest Unveils AI-Powered Web Scanner for Scalable Visual and Accessibility Testing24.10.2025 17:00:00 CEST | Press release

New browser-based solution empowers teams to detect visual bugs and ensure accessibility compliance at scale LambdaTest, a GenAI-native quality engineering platform, today announced the launch of LambdaTest Web Scanner, an advanced browser-based tool combining Visual UI Regression Testing and WCAG-compliant Accessibility Testing. It enables teams to identify and resolve visual and accessibility issues across web applications with unparalleled speed and precision. LambdaTest Web Scanner combines key features to streamline visual and accessibility testing. It offers Visual UI Regression Testing with SmartUI technology, enabling automated scans that detect layout changes and design mismatches across browsers and screen resolutions. It also supports WCAG-compliant Accessibility Testing, identifying violations and providing recommendations for inclusivity. The tool enables cross-browser and responsive testing across multiple browsers and 200+ mobile viewports, while smart scheduling allows

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye